Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Approves 1st Non-Opioid Pain Medicine in 20 Years
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
FDA approves first non-opioid pain medicine in more than 20 years
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time in over two decades that the agency has approved a non-opioid pain drug with a novel mechanism of action.
1d
FDA approves opiate-alternative acute pain management drug, local experts share their thoughts
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
Psychology Today
1d
Treating Pain—Avoiding the Brain
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
News Medical on MSN
18h
Pain coping skills training reduces pain and improves quality of life for dialysis patients
People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...
Everyday Health
1d
FDA Approves First New Type of Pain Medication in More Than 20 Years
Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Journavx
Food and Drug Administration
Feedback